3 - (2 - thiazole - oxy) - 1,2 - epoxipropanderivat as intermediate products for framstellning of 3 - (2 - thiazole - oxy) - propanderivat

摘要

1410512 Thiazoloxymethyleneoxyazolidine derivatives SYNTEX (USA) Inc 17 Oct 1972 [27 Oct 1971 15 Sept 1972] 44865/74 Divided out of 1410511 Heading C2C The invention comprises compounds of the general Formula (III) in which RSP3/SP is in the 4- or 5-position on the thiazole ring and is hydrogen, C 1 -C 6 alkyl, C 3 -C 7 cycloalkyl group, C 1 -C 6 alkoxy, hydroxy (C 1 -C 6 alkyl), acyloxy (C 1 -C 6 alkyl), halo, trifluoromethyl, C 1 -C 12 acyl groups (derived from carboxylic acids), carboxy, cyano, amino optionally substituted by 1 or 2 C 1 -C 6 alkyl groups, formamido, HCONR 1 , RSP1/SP 3 OOC or -C 6 H 3 RSP1/SP 4 RSP1/SP 5 in which RSP1/SP 1 , RSP11/SP 2 and RSP1/SP 2 are C 1 -C 6 alkyl, aryl or arylalkyl; RSP1/SP is C 1 -C 6 alkyl; RSP1/SP 3 is C 1 -C 11 alkyl, C 5 -C 7 cycloalkyl, aryl or arylalkyl; RSP1/SP 4 and RSP1/SP 5 are hydrogen, C 1 -C 6 alkyl, hydroxy (C 1 -C 6 alkyl) or halogen; RSP4/SP and RSP5/SP are hydrogen, C 1 -C 6 alkyl, arylalkyl or together with the carbon atom to which they are attached form a C 5 -C 7 cycloalkyl group; and R 6 is hydrogen, C 1 -C 6 alkyl, aryl or arylalkyl; and pharmaceutically acceptable salts thereof. Those compounds in which RSP4/SP and RSP5/SP are both hydrogen may be prepared by (a) reacting a compound having the formula in which RSP111/SP is hydrogen, C 1 -C 6 alkyl, aryl or arylalkyl with an alkali metal hydride; and (b) reacting the product of (a) with a compound of formula in which X is Br or Cl and RSP3/SP is as defined above. Alternatively the desired compounds may be prepared by treating compounds of Formula (ISP1/SP) with a ketone of formula and aluminium isopropoxide or aluminium t-butoxide or with cycloalkanose in the presence of potassium carbonate. Those compounds of Formula III in which RSP3/SP is alkoxy may be prepared by treating the corrresponding compounds in which RSP3/SP is Br with an alkali metal alkoxide. The products may be obtained as pure optical isomers by using a pure isomer as starting material. Acid addition salts, for example with maleic and hydrochloric acids may be made by standard methods. The products may be used as active agents in pharmaceutical compositions alone or in combination with other pharmaceutically compatible medicaments and the compositions may contain conventional carriers.